Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy

Carlos F Cáceres§,1, Annick Borquez2, Jeffrey D Klausner3,4, Rachel Baggaley5 and Chris Beyrer6

§Corresponding author: Carlos F Cáceres, Center for Interdisciplinary Studies in Sexuality, AIDS and Society, Universidad Peruana Cayetano Heredia, Av. Armendariz 445, Miraflores, Lima 18, Peru. Tel: +51 1 203 3300. (Carlos.caceres@upch.pe)

Abstract

Background: In this article, we present recent evidence from studies focused on the implementation, effectiveness and cost-effectiveness of pre-exposure prophylaxis (PrEP) for HIV infection; discuss PrEP scale-up to date, including the observed levels of access and policy development; and elaborate on key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries.

Discussion: The 2015 WHO Early Release Guidelines for HIV Treatment and Prevention reflect both scientific evidence and new policy perspectives. Those guidelines present a timely challenge to health systems for the scaling up of not only treatment for every person living with HIV infection but also the offer of PrEP to those at substantial risk. Delivery and uptake of both universal antiretroviral therapy (ART) and PrEP will require nation-wide commitment and could reinvigorate health systems to develop more comprehensive “combination prevention” programmes and support wider testing linked to both treatments and other prevention options for populations at highest risk who are currently not accessing services. Various gaps in current health systems will need to be addressed to achieve strategic scale-up of PrEP, including developing prioritization strategies, strengthening drug regulations, determining cost and funding sources, training health providers, supporting user adherence and creating demand.

Conclusions: The initial steps in the scale-up of PrEP globally suggest feasibility, acceptability and likely impact. However, to prevent setbacks in less well-resourced settings, countries will need to anticipate and address challenges such as operational and health systems barriers, drug cost and regulatory policies, health providers’ openness to prescribing PrEP to populations at substantial risk, demand and legal and human rights issues. Emerging problems will require creative solutions and will continue to illustrate the complexity of PrEP implementation.

Keywords: HIV; pre-exposure prophylaxis; implementation science; combination prevention; health systems; acceptability; program cost; scale-up.

Introduction

The timely publication, in September 2015, of the World Health Organization (WHO) Early Release Guidelines on Use of Antiretrovirals for HIV Treatment and Prevention [1] not only confirmed the recommendation of oral HIV pre-exposure prophylaxis (PrEP) as an additional prevention strategy for members of key populations but also extended it to any person at substantial risk. This has reinvigorated discussions on combination prevention, by adding a new, effective prevention choice, and requires efforts to facilitate scale-up where it might be most beneficial.

Globally in mid-2016, PrEP scale-up is just starting. Many countries are beginning to consider if and how PrEP could be employed in their HIV responses to increase impact. To date, roughly 50,000 people are on PrEP in the United States, the country with the greatest experience in PrEP delivery. The U.S. Centers for Disease Control suggest 1.2 million persons at substantial HIV risk, particularly men who have sex with men (MSM), should be on PrEP in the United States [2].

Recently, a number of countries in Africa, Asia, Europe and Latin America have started measures to enable PrEP implementation, such as the approval of tenofovir–emtricitabine for prevention; the inclusion of PrEP in the national prevention policies and guidelines; and the conduct of implementation research or other efforts to define roll-out conditions (see below). Nevertheless, most countries have not taken any steps yet, due to concerns about local relevance, costs and sustainable funding [3], potential competition with treatment expenditures and other health systems issues (e.g. prioritizing potential beneficiary populations, implementation concerns about safety, drug resistance, adherence and “risk compensation”). Stigma and discrimination against some key
populations often result in poor access to health services in general and inadequate prioritization of their needs, contributing to low PrEP awareness among some key population groups. Conversely, some communities of MSM, much more aware of PrEP, are establishing informal channels to obtain PrEP medications in locations where they are officially unavailable and lobbying for PrEP availability.

Building from our 2015 commentary [4], in this article we will present evidence of the implementation process of PrEP programmes in 2015–2016, with data on potential impact and cost-effectiveness when available; discuss correlates of the observed levels of access and policy development; and analyze key emerging policy and research issues to consider for further scale-up, with a special focus on lower-middle income countries (LMIC).

Discussion
Can PrEP curb HIV incidence?
A crucial factor in the relevance of PrEP scale-up in a combination prevention framework is its estimated impact on HIV incidence and cost-effectiveness. A few recent modelling studies, and reviews of such studies, indicate that consideration of the local epidemic context, including the current coverage of other interventions, is key to achieving efficiency:

A systematic review focused on seven modelling studies published in 2015 that evaluated the cost-effectiveness of introducing PrEP. Three of these were in LMIC and investigated the introduction of PrEP among African heterosexual serodiscordant couples. The incremental cost-effectiveness ratio varied between $5000 and $10,000 per disability-adjusted life year (DALY) averted, when PrEP was used for a limited time period before and after the HIV-positive partner had initiated antiretroviral therapy (ART) [5]. In South Africa, such an intervention was found to be cost-effective under a threshold of three times the national GDP/capita. In Nigeria, it was found to be cost-effective under this threshold only if PrEP was integrated in addition to condom promotion and treatment as prevention. In Uganda, PrEP in addition to ART was not found to be cost-effective under this threshold. In all studies, PrEP cost-effectiveness was improved when “infections averted” was used as the outcome (as opposed to DALYs averted), or when taking a longer-term perspective. This is due to PrEP being a prevention intervention, and as such, its impact on HIV-associated DALYs is not apparent on a 10-year or even 20-year time frame.

Another modelling study [6] investigating the introduction of PrEP among women in Western Kenya found that it could have a substantial impact on incidence (22–28% reduction over four years) if implemented alone and that in combination with increased voluntary medical male circumcision and the implementation of 2013 WHO ART guidelines it could reduce incidence by 46–67%, but cost-effectiveness was not evaluated. Cremin and Hallet [7] used Nyanza, Kenya, as a case study to investigate PrEP intervention efficiencies associated with longer residual protection and changes in cost, adherence and prioritization as a function of coverage and time. They found that the ability to adequately prioritize PrEP to groups with high HIV incidence was the strongest determinant of intervention efficiency and highlighted the extent to which dynamic interactions could affect PrEP intervention impact, warning policy makers of the importance of considering the potential effects of programme scale and duration on efficiency.

Mukandavire et al. [8] investigated the impact of PrEP among female sex workers (FSW) in comparison with that of increasing condom use and found that the latter was likely to be larger given its greater efficacy and its effect on both acquisition and transmission, resulting in the protection of both FSW and their clients. When including non-commercial partners of FSW, the relative impact of PrEP over condoms improved but only substantially when the contribution of these partners to HIV transmission was assumed to be high. The authors conclude that PrEP could be a valuable prevention tool among FSW once condom interventions have been maximized and to protect FSW who are unable to increase their condom use. In a study where PrEP introduction among transgender women (TW) sex workers in Peru was considered along with other four strategies, all possible combinations were modelled for joint effectiveness and cost-effectiveness. At current retail Truvada® prices, it was found that the inclusion of PrEP was effective but required lower costs to become cost-effective [9].

The focus of some modelling studies on populations at high risk of infection over limited periods of time and in combination with other interventions, compared to that of earlier modelling studies that explored large PrEP scale-up, suggests the recognition of the need for a strategic implementation of PrEP to increase its cost-effectiveness. In addition, as pointed by Cambiano et al. [5], cost-effectiveness does not necessarily translate into affordability, and therefore, budget impact analyses that carefully consider implementation and funding strategies are the necessary next step to plan for PrEP scale-up.

As of mid-2016, empirical evidence of effectiveness is not yet available from LMIC. In the United States, referrals for and initiation of PrEP increased in clinical practice since 2012, with very low rates of HIV acquisition among adherent PrEP users. However in one study, high rates of sexually transmitted infections (STIs) continue to be reported, as were seen in the delayed arm in PROUD, and reported decreases in condom use were seen in a small subset of PrEP users [2]. Similarly, a three-city demonstration project in the United States found that annualized HIV incidence was very low despite high incidence of other STIs [10], and the pivotal PROUD study among MSM in sexual health clinics in the UK found an effectiveness greater than efficacy in iPrEX, in part due to reaching high-risk individuals who were motivated to take PrEP and whose adherence was high. HIV incidence was very low but bacterial STI incidence has been high, indicating that high-risk MSM are using PrEP and that STI screening is an important part of PrEP delivery [11].

Global PrEP scale-up, as of early 2016
Internationally, HIV prevention implementers and funders are beginning to recognize the potential of PrEP and support implementation efforts (including formative research, demonstration and pilot projects) in lower-middle income countries. By the end of 2016, WHO will be releasing full PrEP
implementation guidelines to support countries to provide PrEP safely and effectively to a range of populations and in various settings. UNAIDS is recognizing PrEP for populations at substantial risk as an important intervention and has included PrEP in the UN global Fast Track prevention targets [12]. The Global Fund to fight AIDS, tuberculosis and malaria is willing to fund PrEP components of combination prevention in eligible countries according to their overall plans and regulations for types of countries [13]. The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) new policy is supporting the provision of PrEP to young women and sex workers in Africa through the DREAMS initiative, as well as to people in serodiscordant couples (as a bridge to antiretroviral therapy in positive partners) and to people at substantial risk in key populations of MSM, female sex workers and injection drug users [14]. UNITAID is considering funding PrEP implementation science projects in LMIC regions [15].

As indicated, the number of countries where any PrEP-related policy has already been put in place is limited (see Table 1). Only three countries − the United States and France and, recently, South Africa, have formally incorporated PrEP in their regular HIV prevention programming. In June 2016, South Africa started to provide PrEP for sex workers as a national programme, and other countries in the region are planning for PrEP and developing national policies and guidelines for implementation. We observe two other kinds of activities: regulatory changes (approval of the use of tenofovir-emtricitabine for PrEP) and an increasing number of ongoing or planned projects and programmes to deliver PrEP.

### Awareness/acceptability of PrEP among stakeholders

As the number of recent studies on PrEP has grown over the past 18 months, here we are focusing on publications from LMIC, as those face greater challenges for implementation.

#### Healthcare providers

Data from LMIC are limited. In a qualitative study in Peru (2014–2015), providers maintain limited awareness about PrEP and express skepticism about its use in prevention, linked to drug complexity, cost and presumed risk compensation [16].

#### General public

A study to explore the public opinion, community interest and perceptions about the use and access to PrEP in Nigeria concluded that increasing PrEP uptake by HIV serodiscordant couples requires motivating the HIV-negative male partners and establishing effective stigma reduction strategies [17].

#### Potential and current users

PrEP use has been associated with feelings of empowerment, agency and safety during sex, and partners’ honesty in sharing

| Country       | TDF-containing drug approved for PrEP | Demonstration projects | National guidelines for PrEP | Source of funding                  |
|---------------|--------------------------------------|------------------------|------------------------------|-----------------------------------|
| Australia     | Effective                             | Ongoing                | Effective                    | Domestic                          |
| Brazil        | Pending                               | Ongoing (1); Pending approval (2) | Planned (3)                  | (1) US NIH; (2) UNITAID; (3) Domestic |
| Canada        | Effective                             |                        |                              | Domestic                          |
| India         | Generic can be sold for prevention    | Planned/ongoing        |                              | BMGF                              |
| France        | Effective                             |                        | Effective (daily and on-demand use) | Domestic                          |
| Kenya         | Effective                             | Planned/ongoing        | Effective                    | BMGF and others                   |
| Malaysia      | Generic can be sold for prevention    |                        | Effective                    | Out of pocket                      |
| Mexico        | –                                    | Pending approval       |                              | UNITAID                           |
| Mozambique    | –                                    | Planned/ongoing        |                              | BMGF and others                   |
| Peru          | Effective                             | Ongoing (1); Pending approval (2) | Planned/ongoing              | (1) amfAR; (2) UNITAID; (3) Several sources |
| Philippines   | –                                    | Planned/ongoing        | Effective                    | Several (domestic and foreign)    |
| South Africa  | Effective                             | Planned/ongoing        | Effective                    | Several (domestic and foreign)    |
| Thailand      | Generic can be sold for prevention    | Ongoing/planned/approval | Effective for out-of-pocket use | Several (domestic and foreign)    |
| United States | Effective                             | Completed/approval     | Effective                    | Domestic                          |
| United Kingdom| –                                    | Completed/ongoing      | Pending                      | Domestic                          |
| Zimbabwe      | –                                    | Ongoing/approval       |                              | Several sources                   |

BMGF, Bill and Melinda Gates Foundation; PrEP, pre-exposure prophylaxis.
In high-income countries and in upper-middle income signatories of free-trade agreements, tenofovir-emtricitabine (TDF-FTC) is only available as very costly Truvada® (although the expiration of its patent protection in 2017 may change this). Conversely, generic TDF-FCT is already being produced and is available for less than USD10 per month, for the benefit of LMIC with a high burden of HIV infection [26]. Some United Nations partners have established regional procurement mechanisms to increase drug access, too.

### Selecting the right drug

Clinical trials such as Partners’ PrEP showed comparable efficacy between the TDF-FTC and tenofovir-only arms [27]; likewise, the Bangkok PrEP study also found efficacy for a TDF-based PrEP regime for people who inject drugs [28]. Given the partial availability of TDF-FTC in the world at present, the WHO recommendations defined oral PrEP as the use of tenofovir-containing pills. Although high efficacy for TDF alone was found for the prevention of heterosexual HIV transmission, its comparative effectiveness in preventing HIV transmission in anal sex between men is not proven. In addition, given the treatment equivalence of lamivudine (3TC) and FTC, and higher availability of such drug in some countries, WHO guidance is forthcoming on 3TC as an alternative to FTC in combination with TDF for PrEP.

### Ensuring safety

Based on the evidence available, the WHO Early Release Recommendations [1] for HIV Treatment and Prevention in both higher- and LMIC have indicated that before starting PrEP, subjects’ baseline renal function should be assessed, together with HIV status [1]. Safety monitoring data from PrEP programmes in LMIC are still not available. To assess the relative importance of the adverse effects of TDF-FTC used for PrEP, a recent study compared the number needed to harm (NNH) for TDF-FTC in MSM, transwomen and seronegative partners in heterosexual serodiscordant couples, with adverse effects of aspirin used for the prevention of cardiovascular disease among middle-aged men and women [29]. It was found that, if the populations and the frequency of use are comparable, the NNH for TDF-FTC compared favourably with the NNH for aspirin concerning adverse effects.

### Defining delivery models with appropriate monitoring and optimal adherence

The administration of PrEP implies coordination of various components: initial eligibility assessment (including HIV testing), regular follow-up testing, safety and adherence monitoring, and drug supply. HIV testing is fundamental to confirm eligibility and rule out subsequent infection. As HIV testing and counselling in LMIC is often facility-based, to increase testing of people at substantial HIV risk who do not visit clinical services, other approaches such as workplace, outreach, mobile and potentially HIV self-testing should be considered [30,31]. Links with community-based organizations and key population networks to support linkage following testing are essential to ensure people living with HIV link to ART services and that those HIV-negative link to prevention services where PrEP and other options are available.
Meaningful, effective community involvement is the other Involving communities and dealing with structural barriers additional support in this task [46].

Integration of PrEP with relevant services will increase sustainability and foster comprehensive care. Recent programmatic data from the United States indicate that as PrEP programmes must deal with substantial rates of other STI, they provide an opportunity to integrate periodic STI screening and management [33].

The various barriers to reaching and delivering services for adolescent girls and young women in settings of high incidence in southern and Eastern Africa [34–37] should be identified and tackled [38]. Demonstration projects to explore PrEP implementation in those populations are a priority. Medication adherence in younger women has also been recognized as a significant challenge [39,40]. Risk assessment tools have been designed for men who have sex with men (MSM) and people who inject drugs (PWID), but have not been critically evaluated yet in terms of their usefulness in PrEP implementation. Regardless of population and point of entry, evidence-based strategies to support adherence should be considered, without losing a user-centred approach, where risk reduction is the goal – rather than PrEP adherence per se [41]. Within the Partners PrEP study among HIV-negative members of serodiscordant couples in Kenya and Uganda, objective measures of PrEP adherence were collected using unannounced home-based pill counts and electronic pill bottle monitoring; participants received individual and couples-based adherence counselling at PrEP initiation and throughout the study; participants were followed monthly and counselling was intensified if unannounced pill count adherence fell to <80%. Median adherence was 99.1% (IQR 96.9–100%) by unannounced pill counts and 97.2% (90.6–100%) by electronic monitoring over 807 person-years [42].

**Improving provider training**

Given the need to prioritize individuals at high risk of infection to improve PrEP cost-effectiveness, training of health providers to better identify potential PrEP beneficiaries will be important. Sexual history training among a sample of U.S. physicians resulted in increased frequency of documented sexual history discussions and greater comfort with sexual health discussions [43]. Risk assessment tools relying on self-reported risk behaviours to estimate HIV risk have been successfully implemented among MSM [44] and PWID [45]. Applying algorithms to routinely collect behavioural or STI history data from patients’ electronic health records provides additional support in this task [46].

**Involving communities and dealing with structural barriers**

Meaningful, effective community involvement is the other key factor in PrEP scale-up [47]. The prevailing legal and human rights barriers to access care affecting MSM, TW and sex workers may pose significant challenges to providing PrEP to these key populations, in many settings, particularly in LMIC in Africa and the Caribbean where homosexuality and sex work remain criminalized [48,49]. PrEP scale-up for key populations provides an opportunity to improve services and increase service utilization among key populations as well as possibility of “programmatic risk” [50].

**Using implementation research**

Focused implementation research can be used to resolve some of the challenges described above, such as dynamic stakeholders’ attitudes and information needs; PrEP awareness and demand creation; best options for the target drug (i.e. source, purchase mechanism and funding); refinement of target population(s); programme organization, modes of delivery and integration with other services; health provider training; and strategies to manage STIs and tackle structural barriers to programmatic success [51].

**Conclusions**

The 2015 WHO recommendation to support the offer of PrEP to people at substantial HIV risk was based on compelling effectiveness evidence to prevent HIV acquisition in various populations. To date, PrEP implementation outside the United States seems to be moving to a new phase, given increasing numbers of demonstration and pilot programmes underway or being considered. The challenge is to learn from those and support wider use for populations that continue to experience high incidence and for whom additional prevention choices are needed. Community advocates and networks in many countries are leading the demand for greater access. Many challenges remain for implementation in LMIC, but the evidence of effectiveness of PrEP, the acceptability and uptake by people who could benefit most and the cost-effectiveness of PrEP if offered to people at highest risk are compelling reasons to push for greater availability and implementation. It is hoped that future long-acting formulations such as injectable [52] will be effective, and the experience gained from implementing daily PrEP will be crucial to facilitate their introduction.

**Authors’ affiliations**

1.Center for Interdisciplinary Studies in Sexuality, AIDS and Society, Universidad Peruana Cayetano Heredia, Lima, Peru; 2.Division of Global Public Health, University of California, San Diego, CA, USA; 3.David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 4.Fielding School of Public Health, University of California, Los Angeles, CA, USA; 5.Center for Public Health and Human Rights, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MA, USA

**Competing interests**

The authors declare that they have no conflict of interest.

**Authors’ contributions**

CFC wrote the first draft and managed the subsequent versions. AB and RB proposed text and references for specific sections and general suggestions for the full text. JDK and CB provided suggestions for specific topics. All authors have read and approved the final version.

**Acknowledgements**

The authors are grateful to Ioannis Mameletis and Rosalind Coleman for contributing important data to this paper. AB thanks the University of
References

1. WHO. Early release guidelines for the use of ARVs in HIV treatment and prevention. Geneva: WHO; 2015.
2. Vell J, Marcus JL, Phengprasamy, T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV pre-exposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1603–3. doi: http://dx.doi.org/10.1093/cid/cv778
3. Statement on PrEP from Community organisations working on HIV Prevention. [cited 2016 Feb 12]. Available from: www.prepaccess.org.uk
4. Cáceres CF, Koochich F, Giovinco P, Sow PS, O’Reilly K, Mayer KH, et al. The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc. 2015;18(Suppl 3):19494. doi: http://dx.doi.org/10.7448/IAS.18.1.A19494
5. Cambiao V, Miners A, Phillips A. What do we know about the cost-effectiveness of HIV pre-exposure prophylaxis, and is it affordable? Curr Opin HIV AIDS. 2016;11(1):56–66. doi: http://dx.doi.org/10.1097/COH.0000000000000217
6. Blaizot S, Maman D, Riche B, Mukui I, Kirubi B, Ecorchard R, et al. Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. BMC Infect Dis. 2016;16(1):189. doi: http://dx.doi.org/10.1186/s12879-016-1520-4
7. Clermont-T. Estimating the range of potential epidemiological impact of pre-exposure prophylaxis: run-away success or run-away failure? AIDS. 2015;29(6):733–8. doi: http://dx.doi.org/10.1097/QAD.0000000000000591
8. Mukandavire Z, Mitchell KM, Vickerman P. Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers. Epidemics. 2016;14:62–70. doi: http://dx.doi.org/10.1016/j.epidem.2015.10.002
9. Borquez A, Guanira J, Caballero P, Silva-Santisteban A, Salazar X, Halliet T, et al. Comparing impact and cost-effectiveness of combinations of HIV prevention interventions among transgender women sex workers in Lima, Peru using mathematical modelling informed by a stakeholder analysis and health system capacity evaluation. Oral Presentation, World STI Congress; 2015
10. Liu AT, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Pre-exposure prophylaxis for HIV infection integrated with Municipal- and health system capacity evaluation. Oral Presentation, World STI Congress; 2015
11. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One. 2012;7(4):e33103. doi: http://dx.doi.org/10.1371/journal.pone.0033103
12. Holtz T, Chitwarekam A, Curnel ME, Hughes J, Amico KR, Hendrix C, et al. HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand. Abstract Supplement, 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2015 Jul 19–22. Vancouver, Canada; 2015. p. 25–26
13. Nezer K, Nezer K, Lurie A, Odoyo J, Tindimwebwa E, Morton J, et al. Sustained PrEP use among high-risk African HIV Serodiscordant couples participating in a PrEP demonstration project. Conference on Retroviruses and Opportunistic Infections; 2015 Feb 23–26. Seattle. 2015.
14. Ngure K, Nezer K, Curran K, Vusha S, Ngutu M, Mugo N, et al. We knew I would be Safer. Experiences of Kenyan HIV Serodiscordant Couples Soon After Pre-Exposure Prophylaxis (PrEP) Initiation. AIDS Patient Care STDS. 2016;30(2):78–83. doi: http://dx.doi.org/10.1089/apc.2015.0259
15. Ouellet E, Durand M, Guenther JT, LeLorier J, Tremblay CL. Cost effectiveness of “on demand” HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. J Infect Dis Medi. 2015;26(1):23–9. doi: http://dx.doi.org/10.1093/infdis/jiv365
16. NHS England News. Update on commissioning and provision of Pre-Exposure Prophylaxis (PrEP) for HIV prevention. 21 March 2016. [cited 2016 June 27]. Available from: https://www.england.nhs.uk/2016/03/03/prep/
17. UNAIDS. Oral pre-exposure prophylaxis: putting a new choice in context. Geneva: UNAIDS; 2015;
18. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. doi: http://dx.doi.org/10.1056/NEJ- Moa1108524
19. Choopanya K, Martin M, Sontharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Thailand (the Bangkok Tenofiv Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. doi: http://dx.doi.org/10.1016/S0140-6736(13)61277-7
20. Kojima N, Klausner J. Is Emtricitabine-Tenofovir Disoproxil Fumarate pre-exposure prophylaxis for the prevention of HIV infection safer than aspirin? Open Forum Infect Dis. 2016;3(1):off211. doi: http://dx.doi.org/10.1093/ofid/off211
21. Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, Reynolds SJ. Combination implementation for HIV prevention: moving from clinical trial to community implementation at population-level effectiveness. Lancet Infect Dis. 2013;13:65–76. doi: http://dx.doi.org/10.1016/S1473-3099(12)70273-6
22. Lamargne J, Balestre E, Orne-Gilemmann I, Iwui C, Okosola N, Newell ML. Asymptomatic HIV infection through repeat home-based testing in the context of a treatment as prevention trial in rural South Africa. AIDS Res Hum Retroviruses. 2015;30(S1):A287. doi: http://dx.doi.org/10.1089/aid.2014.5650.abstract
23. Liu A, Cohen S, Follansbee S, Cohen D, Weber S, Sachdev D, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11:e1001613. doi: http://dx.doi.org/10.1371/journal.pmed.1001613
24. UNAIDS. Prevention and treatment of sexually-transmitted diseases. [cited 2016 Feb 12]. Available from: https://www.unaids.org/en/resources/documents/2015/UNAIDS_PCBP37_15-18
25. Naik S. Antiretroviral therapy in children. Pediatr Infect Dis J. 2015;34(11 Suppl):S1–8. doi: http://dx.doi.org/10.1097/INF.0000000000000386
26. Thirumurthy H, et al. Lay social resources for support of adherence to antiretroviral prophylaxis for HIV prevention among African HIV Serodiscordant couples in sub-Saharan Africa: a qualitative study. AIDS Behav. 2015;19(5):811–20. doi: http://dx.doi.org/10.1007/s10461-014-0899-4
27. Roberts S, Celum C, Mugo N, Haberer J, Cohen CL, Inungu E, et al. Intimate partner violence is associated with low PrEP adherence in African women. Abstract 980, CROI Conference; 2015 Feb 23–26. [2015 March 12]. Available from: http://www.croiconference.org/sessions/intimate-partner-violence-associated-low-prep-adherence-african-women
28. Thomson K, Haberer J, Celum C, Mujugira A, Ndase P, Hendrix C, et al. Medication sharing among African HIV Serodiscordant couples enrolled in a PrEP trial. Abstract 988, CROI Conference; 2015 Feb 23–26. [2015 March 12]. Available from: http://www.croiconference.org/sessions/medication-sharing-among-african-hiv-serodiscordant-couples-enrolled-prep-trial
29. Thomson K, Haberer J, Celum C, Mujugira A, Ndase P, Hendrix C, et al. Medication sharing among African HIV Serodiscordant couples enrolled in a PrEP trial. Abstract 988, CROI Conference; 2015 Feb 23–26. [2015 March 12]. Available from: http://www.croiconference.org/sessions/medication-sharing-among-african-hiv-serodiscordant-couples-enrolled-prep-trial
37. Bekker LG, Hughes J, Amico R, Roux S, Hendrix C, Anderson PL, et al. HPTN 067/ADAPT Cape Town: a comparison of daily and nondaily PrEP dosing in African women. Abstract 978LB, CROI Conference; 2015 Feb 23 –26. [cited 2016 Aug 5]. Available from: http://www.croiconference.org/sessions/hptn067adaptneddailypr-cape-town-comparison-daily-and-nondaily-pr-dosing-african-women

38. Celum CL, Delany-Moretlwe S, McConnell M, van Rooyen H, Bekker LG, Kurth A, et al. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc. 2015;18(Suppl 3):20227. doi: http://dx.doi.org/10.7448/IAS.18.4.20227. eCollection 2015.

39. Geary CW, Bukusi EA. Women and ARV-based HIV prevention: challenges and opportunities. J Int AIDS Soc. 2014;17(Suppl 2):19356. doi: http://dx.doi.org/10.7448/IAS.17.3.19356. eCollection 2014.

40. van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(Suppl 2):19146. doi: http://dx.doi.org/10.7448/IAS.17.3.19146. eCollection 2014.

41. Haberer J. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11(1):10–7. doi: http://dx.doi.org/10.1097/COH.0000000000000220

42. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511. doi: http://dx.doi.org/10.1371/journal.pmed.1001511

43. Lanier Y, Castellanos T, Barrow RY, Jordan WC, Caine V, Sutton MY. Brief sexual histories and routine HIV/STD testing by medical providers. AIDS Patient Care STDS. 2014;28:113–20. doi: http://dx.doi.org/10.1089/apc.2013.0328

44. Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;62:421–7. doi: http://dx.doi.org/10.1097/QAI.0b013e318256b216

45. Smith DK, Pan Y, Rose CE, Pals SL, Mehta SH, Kirk GD, et al. A brief screening tool to assess the risk of contracting HIV infection among active injection drug users. J Addict Med. 2015;9:226–32. doi: http://dx.doi.org/10.1097/ADM.0000000000000123

46. Vogel J, Brown JS, Land T, Platt R, Klompas M. MDPHinet: secure, distributed sharing of electronic health record data for public health surveillance, evaluation, and planning. Am J Public Health. 2014;104:2265–70. doi: http://dx.doi.org/10.2105/AJPH.2014.302103

47. Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis in clinical practice. J Acquir Immune Defic Syndr. 2015;55(1):8–13. doi: http://dx.doi.org/10.1097/QAI.0000000000000964

48. Liu Y, Sun X, Qian H, Yin L, Yan Z, Wang L, et al. Qualitative assessment of barriers and facilitators of access to HIV testing among men who have sex with men in China. AIDS Patient Care STDS. 2015;29(9):481–9. doi: http://dx.doi.org/10.1089/apc.2015.0083

49. Taegtmeyer M, Davies A, Mwangome M, van der Elst EM, Graham SM, Price MA, et al. Challenges in providing counseling to MSM in highly stigmatized contexts: results of a qualitative study from Kenya. PLoS One. 2013;8(6):e64527. doi: http://dx.doi.org/10.1371/journal.pone.0064527

50. Caceres CF, O’Reilly K, Mayer K, Baggaley R. PrEP implementation: moving from trials to policy and practice. J Int AIDS Soc. 2015;18(Suppl 3):20222. doi: http://dx.doi.org/10.7448/IAS.18.4.20222

51. Hankins C, Macklin R, Warren M. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc. 2015;18(Suppl 3):19973. doi: http://dx.doi.org/10.7448/IAS.18.4.19973. eCollection 2015.

52. Margolis D, González-García J, Stellbrink H, Eron JJ, Yazdanpanah Y, Griffin S, et al. Cabotegravir + Rilpivirine as long-acting maintenance therapy: LATTE-2 week 32 results. Abstract 31LB. CROI Conference, February 22–25, 2016, Boston, MA. [cited 2016 Aug 5]. Available from: http://www.croiconference.org/sessions/cabotegravirrilpivirine-long-acting-maintenance-therapy-latte-2-week-32-results